All Access

Health Tech Deals

Health Tech Deals Alerts

Alert

Standard

Health Tech Deals Thought Bubble

Thought Bubble

mustard

BFD Expert Voices - Health Tech Deals

BFD Expert Voices

topics

politics-policy

epstein-files

donald-trump

2026-midterm-elections

immigration

behind-the-curtain

race-and-equity

technology

privacy-tech-regulation

automation-and-ai

tiktok-news

big-tech

social-media

cybersecurity

economy

social-security

inflation

tariffs

federal-reserve

jobs

transportation

business

stock-market-news

retail-news

crypto

media

elon-musk

dealmaking

health

rfk-jr

drug-prices

axios-explains-abortion

public-health

world

israel

axios-explains-ukraine

iran

russia

china

energy-climate

nuclear-energy

climate-energy-policy

climate-change

extreme-weather

alternative-energy

electric-vehicles

science

emerging-tech

biomedicine

newsletters

pittsburgh

atlanta

san-diego

charlotte

boulder

washington-dc

kansas-city

dallas

denver

detroit

des-moines

austin

boston

chicago

cleveland

columbus

houston

indianapolis

miami

nashville

new-orleans

nw-arkansas

philadelphia

phoenix

portland

richmond

salt-lake-city

san-antonio

san-francisco

seattle

tampa-bay

twin-cities

raleigh

huntsville

colorado-springs

axios-local

axios-pro

axios-live

the-axios-show

Leadoptik CEO Reza Khorasaninejad is attempting no small scientific feat: developing human hair-sized technology to help doctors spot lung cancer early.

Why it matters: The company raised $5 million in seed funding led by MetaVC Partners with support from Sony Innovation Fund, SOSV, and others, Khorasaninejad tells Axios exclusively.

Details: Funds will go toward hiring, product development, clinical studies, and pursuing regulatory approval from the Food and Drug Administration.

Khorasaninejad expects Leadoptik to raise a Series A in the summer of 2024.

How it works: The San Jose, California-based company is building a probe to navigate narrow airways and imaging systems to enable real-time imaging, tumor detection and biopsy guidance.

Leadoptik is working with nano-sized materials (a human hair is about 60,000 nanometers thick) with the bold goal of enabling surgeons to see objects 50 times smaller than today’s imaging systems permit.

A core component of its imaging technology is the ability to adapt to movement inside the lungs — as patients breathe — with what it calls adaptive focusing, which makes use of multiple focal spots rather than one to capture a high-resolution image.

"Most of the time technologies today are blind. They take tissue near the nodule and collect it without real-time imaging," says Khorasaninejad. "We can see where the needle goes, when it punctures the nodule, and where we take tissue from."

What they're saying: MetaVC managing partner Conrad Burke tells Axios he foresees interest from academic medical centers and hospitals in Leadoptik's imaging devices.

What's happening: Leadoptik is targeting hospitals in areas with the largest lung cancer biopsy volume such as Los Angeles, Florida and New York.

The company is also pursuing FDA clearance as a Class II medical device under the 510(k) pathway.

Importantly, Leadoptik is not attempting to diagnose lung cancer but rather to assist clinicians in identifying it.

Flashback: Khorasaninejad, a former Harvard research associate whose 2016 paper on high-end optical lenses landed him on the cover of Science magazine, built a prototype of Leadoptik's system in his garage in 2020.

That's where he met Burke, who says he was attracted by Khorasaninejad's "infectious energy."

"He called it speed dating," says Khorasaninejad. "We did that for a year and then he became interested in leading this round."

State of play: Most of Leadoptik's potential rivals are publicly traded medical device and imaging giants that manufacture one of the two components of Leadoptik's system. For example...

Boston Scientific (NYSE: BSX) has a market cap of $76.7 million.

Olympus, based in Japan, has a market cap of $2.89 trillion.

Exclusive: Leadoptik pursues miniature feat in "seeing" lung cancer

The seed round was led by MetaVC Partners.

Illustration of a stethoscope in the shape of a pair of lungs

Health tech deals

Leadoptik CEO Reza Khorasaninejad is attempting no small scientific feat: developing human hair-sized technology to help doctors spot lung cancer early.Why it matters: The company raised $5 million in seed funding led by MetaVC Partners with support from Sony Innovation Fund, SOSV, and others, Khorasaninejad tells Axios exclusively.

Exclusive: Leadoptik pursues miniature feat in "seeing" lung cancer

What to read next